4.55

8.59% 0.36

After Hours: 4.56 0.010 +0.22%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $4.55, with a volume of 992.96K. It is up +8.59% in the last 24 hours and down -22.75% over the past month. C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Previous Close:

$4.19

Open:

$4.23

24h Volume:

992.96K

Relative Volume:

1.01

Market Cap:

$312.71M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-1.5965

EPS:

-2.85

Net Cash Flow:

$-108.55M

1W Performance:

+12.35%

1M Performance:

-22.75%

6M Performance:

-16.97%

1Y Performance:

+203.33%

1-Day Range:

$4.23

$4.65

1-Week Range:

$3.89

$4.65

52-Week Range:

$1.06

$11.88

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

145

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	4.55	312.71M	20.76M	-132.49M	-108.55M	-2.85
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

Nov 25, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Nov 25, 2024

Nov 22, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 22, 2024

Nov 21, 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 21, 2024

C4 Therapeutics appoints Steve Hoerter to board By Investing.com - Investing.com Nigeria

Nov 21, 2024

Nov 20, 2024

C4 Therapeutics Appoints Steve Hoerter to Board - TipRanks

Nov 20, 2024

C4 Therapeutics appoints Steve Hoerter to board - Investing.com

Nov 20, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - The Manila Times

Nov 20, 2024

C4 Therapeutics Adds Oncology Veteran Steve Hoerter to Board, Brings Drug Launch Expertise | CCCC Stock News - StockTitan

Nov 20, 2024

C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors - Marketscreener.com

Nov 20, 2024

Nov 19, 2024

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Nov 19, 2024

Nov 18, 2024

Stephens Initiates Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat

Nov 18, 2024

Stephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight Recommendation - MSN

Nov 18, 2024

Nov 16, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest - MarketBeat

Nov 16, 2024

Nov 15, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 15, 2024

Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc - GuruFocus.com

Nov 15, 2024

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St

Nov 15, 2024

Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024

Nov 11, 2024

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 11, 2024

Nov 08, 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 08, 2024

Nov 06, 2024

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout - Seeking Alpha

Nov 06, 2024

CCCCC4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial - The Manila Times

Nov 06, 2024

C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances | CCCC Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 05, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 05, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com

Nov 05, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times

Nov 05, 2024

C4 Therapeutics' Cemsidomide Trial Data Selected for Key ASH Presentations in NHL, Myeloma | CCCC Stock News - StockTitan

Nov 05, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 05, 2024

Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 04, 2024

Nov 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Nov 01, 2024

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks

Nov 01, 2024

Oct 31, 2024